SEC Comment Letter 0000000000-23-003502 to ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682) (NDRA)

ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)
Date: April 7, 2023 · CIK: 0001681682 · Accession: 0000000000-23-003502

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-271003

Date

April 7, 2023

Author

Not clearly detected

Form

UPLOAD

Company

ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)

Letter

United States securities and exchange commission logo April 7, 2023 Francois Michelon President and Chief Executive Officer ENDRA Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor, MI 48105-1570 Re:ENDRA Life Sciences Inc. Registration Statement on Form S-1 Filed March 30, 2023 File No. 333-271003 Dear Francois Michelon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Coleman Wombwell, Esq.

Show Raw Text

United States securities and exchange commission logo
April 7, 2023
Francois Michelon
President and Chief Executive Officer
ENDRA Life Sciences Inc.
3600 Green Court, Suite 350
Ann Arbor, MI 48105-1570
Re:ENDRA Life Sciences Inc.
Registration Statement on Form S-1
Filed March 30, 2023
File No. 333-271003
Dear Francois Michelon:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Coleman Wombwell, Esq.

SecProbe.io